Research programme: cephalosporin antibacterials - Procter and Gamble

Drug Profile

Research programme: cephalosporin antibacterials - Procter and Gamble

Alternative Names: 3-dithiocarbamoylcarbacephalosporins research programme - Procter and Gamble; Antibacterials research programme - Procter and Gamble; PGE 6737410; PGE 856854; PGE 9739390; PGE 9882816; PGE 9951357

Latest Information Update: 05 Mar 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Procter & Gamble
  • Class
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Gram-positive infections

Most Recent Events

  • 05 Mar 2003 No development reported - Preclinical for Gram-positive infections in USA (unspecified route)
  • 16 Oct 2000 Preclinical development for Gram-positive infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top